Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Novo Nordisk A/S Class B (NOVG)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
115.60 -0.20    -0.17%
17/04 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  DK0062498333 
S/N:  A3EU6F
  • Volume: 4,558
  • Bid/Ask: 115.60 / 117.18
  • Day's Range: 115.42 - 117.86
Novo Nordisk B 115.60 -0.20 -0.17%

CSE:NOVG Financials

 
A brief overview of the CSE:NOVOb financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Novo Nordisk A/S Class B over time.

Novo Nordisk A/S reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was DKK 58,731 million compared to DKK 45,566 million a year ago. Net income was DKK 22,478 million compared to DKK 14,405 million a year ago.For the nine months, sales was DKK 166,398 million compared to DKK 128,862 million a year ago. Net income was DKK 61,720 million compared to DKK 41,933 million a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

NOVG Income Statement

Gross margin TTM 84.6%
Operating margin TTM 44.77%
Net Profit margin TTM 36.03%
Return on Investment TTM 68.52%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 65863 58731 54300 53367
Gross Profit 55849 49018 46444 45185
Operating Income 28180 26913 23888 25007
Net Income 21963 22478 19428 19814

NOVG Balance Sheet

Quick Ratio MRQ 0.56
Current Ratio MRQ 0.82
LT Debt to Equity MRQ 14.99%
Total Debt to Equity MRQ 25.34%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 314486 300101 280753 250025
Total Liabilities 207925 207110 190280 170151
Total Equity 106561 92991 90473 79874

NOVG Cash Flow Statement

Cash Flow/Share TTM 24.43
Revenue/Share TTM 52.1
Operating Cash Flow  5.63%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 9551 40966 28577 29814
Cash From Investing Activities -14717 -13243 -9285 -6647
Cash From Financing Activities -10116 -19832 -12589 -20621
Net Change in Cash -15491 8309 6638 2283
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

NOVOb Comments

Write your thoughts about Novo Nordisk A/S
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
HH HH
HH HH Jun 12, 2023 8:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
My investment propensity test was surprising that Jim Simon, a Renaissance technology, had the most stocks he owned, but it was even more surprising that Novo Nordisk AS. Because it was the only event I recommended to my friend. HHH
Reply
0 0
Report
Terrible Investor
TerribleInvestor Apr 13, 2023 7:51AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Boooooom! 30%.
Reply
1 0
Report
Terrible Investor
TerribleInvestor Jan 03, 2023 11:59PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Very very bullish!
Reply
1 4
Report
Terrible Investor
TerribleInvestor Jan 03, 2023 11:59PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Those dislikes didnt age well
Reply
0 0
Report
Karsten Vester
Karsten Vester Jan 03, 2023 11:59PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Dislikes dont know anything obviously
Reply
0 0
Report
Toby Brunt
Toby Brunt Apr 19, 2022 5:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Does anyone no of a particular reason that NOVO B is going so far down today? Is it profit taking before Q1 2022 results?
Reply
0 0
Report
HH HH
HH HH Apr 19, 2022 5:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I used to do the same thing. In the case of novice investment, we try to find out the reason for the fall and rise in stock prices. It's a futile act. The rise and fall in stock prices are just for Manipulators to move in a predetermined scenario. So a successful investment is a quick insight into Manipulators' scenarios. HHH
Reply
1 0
Report
Sandy SS
Sandy SS Feb 09, 2022 8:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
New Target 825 by EOM
Reply
1 1
Report
Sandy SS
Sandy SS Feb 09, 2022 8:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
New Target 825
Reply
1 0
Report
Terrible Investor
TerribleInvestor Nov 25, 2021 5:10AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Consolidating nicely for leg up to 850!🌟
Reply
1 0
Report
Ralf Adams
Ralf Adams Feb 11, 2021 4:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Results from clinical study just published in New England Journal of Medicine: Impressive new weight loss results for Semaglutide at only 2.4 mg once a week. Drug mimics the gut hormone glucagon-like peptide-1 (GLP-1) that is secreted by your gut after eating.
Reply
0 1
Report
Candy Man
Candy Man Jan 14, 2021 4:16PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Now is the time to buy - novo is very seasonal stock goes up the most in jan/feb.
Reply
1 0
Report
Carlos Andres
Carlos Andres Aug 25, 2020 4:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
bullish??
Reply
2 0
Report
Carlos Andres
Carlos Andres Aug 25, 2020 4:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
No. Funds are selling. Time to wait to go long...
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email